Meningitis

Orphan designation: (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol bedaquiline Treatment of tuberculosis, 26/08/2005 Withdrawn

Retrieved on: 
Wednesday, April 3, 2024
Community, Civil service commission, Eurostat, Sneeze, Diagnosis, Granuloma, Cough, Prevalence, Cell, Disease, Infection, Tuberculosis, Central nervous system, Patient, Committee, Knowledge, Seriousness, Regulation, Bacteria, Meningitis, EMA, MDR TB, IRIS, Joint, Antimycobacterial, Periodic breathing, MDR, European, Fever, COMP, Safety, European Commission, Marketing, Lymphatic system, Pharmaceutical industry

Orphan designation: (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol bedaquiline Treatment of tuberculosis, 26/08/2005 Withdrawn

Key Points: 


Orphan designation: (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol bedaquiline Treatment of tuberculosis, 26/08/2005 Withdrawn

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Retrieved on: 
Monday, March 4, 2024
SAN, Immunization, PCV, Serology, Life, Vaccine, Safety, Meningitis, Genetically modified bacteria, IPD, Tolerability, Infant, Disease, Streptococcus pneumoniae, Fungal infection

SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.

Key Points: 
  • Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.
  • “Completing enrollment of the VAX-24 study with more than 800 healthy infants demonstrates yet another significant milestone in the development of our VAX-24 and VAX-31 PCV candidates,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • “We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market or in U.S. clinics today.
  • “Given the significant burden of disease in young children, there remains a need for broader-spectrum vaccines like VAX-24 and VAX-31, our next-generation 31-valent PCV candidate, that are designed to provide greater protection than the current standard-of-care.”

Antibiotic Drugs Market Analysis Report 2024: Surging Demand, Trends, and Forecasts 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024
Health, Pharmaceutical, Pfizer, Urinary tract infection, Merck, USD, GSK, Strategic planning, Cephalosporin, Pneumonia, Prevalence, Merck & Co., Meningitis, Infection, Pharmaceutical industry

The "Global Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.
  • The report meticulously evaluates the antibiotic drugs industry's landscape, emphasizing the key drug classes such as Cephalosporins, Penicillins, Macrolides, and Fluoroquinolones.
  • This investigation aligns with an increased emphasis on antibiotic stewardship and the urgent need for combating antibiotic resistance globally.
  • The Antibiotic Drugs Market report not only underscores the significant trends and growth drivers but also furnishes a detailed forecast, setting the stage for informed decision-making and strategic planning within the pharmaceutical sector.

THE AMERICAN SOCIETY FOR MENINGITIS PREVENTION (ASMP) LAUNCHES TO ADDRESS GROWING NEED FOR MENINGITIS PREVENTION EDUCATION IN THE UNITED STATES

Retrieved on: 
Thursday, March 7, 2024
BSN, RN, Education, Project, Parent, ASMP, MBA, Meningococcal disease, Vaccination, Society, Meningitis, Mother, Patient, Policy, MPH, Genetically modified bacteria, Pharmaceutical industry

FARMINGTON HILLS, Mich., March 7, 2024 /PRNewswire/ -- The American Society for Meningitis Prevention (ASMP) launched today to empower Americans to take action to prevent meningococcal meningitis, a life-threatening bacterial infection. Founded by Patti Wukovits and Alicia Stillman, two mothers who tragically lost their daughters to meningococcal meningitis, ASMP aims to raise awareness among adolescents, young adults, parents, healthcare providers, and policymakers about meningococcal meningitis and the critical role of comprehensive vaccination in preventing it.

Key Points: 
  • FARMINGTON HILLS, Mich., March 7, 2024 /PRNewswire/ -- The American Society for Meningitis Prevention (ASMP) launched today to empower Americans to take action to prevent meningococcal meningitis, a life-threatening bacterial infection.
  • To help protect against meningococcal meningitis, patients must be vaccinated against all five types of meningococcal bacteria most likely to cause meningococcal meningitis: A–B–C–W–Y.ii
    "Meningitis prevention education is more important in the U.S. today than ever.
  • Starting today, the American Society for Meningitis Prevention will replace the Meningitis B Action Project.
  • To learn more about the American Society for Meningitis Prevention, visit meningitisprevention.org .

QIAGEN expands business in Middle East with new regional headquarters and major projects

Retrieved on: 
Wednesday, January 3, 2024
EEMEA, Workforce, TST, TB, CDC, Policy, QCI, Medicine, Commercial, Infection, Cervical cancer, Marketing, QGEN, QIAGEN, WHO, Disease, HPV, Incidence, Latent tuberculosis, Language interpretation, Vaccination, QDI, BCG, Meningitis, Ministry, Public, World Health Organization, Memorandum of understanding, Patient, Bacteria, Gold

“At QIAGEN, we believe that improving healthcare outcomes starts with a strong foundation of collaboration and innovation, and we are excited to play a crucial role in advancing health and well-being throughout the Middle East.

Key Points: 
  • “At QIAGEN, we believe that improving healthcare outcomes starts with a strong foundation of collaboration and innovation, and we are excited to play a crucial role in advancing health and well-being throughout the Middle East.
  • To accommodate its growing regional presence and customer needs, QIAGEN will inaugurate its new regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024.
  • This office will further strengthen the company’s commitment to the Middle East and improve its ability to serve clients in the area.
  • The CDC and WHO endorse the use of QuantiFERON-TB Gold Plus in all settings to combat the global TB epidemic.

Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate

Retrieved on: 
Tuesday, January 2, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, PCV, Risk, Death, Pneumonia, Streptococcus, Disease, Ageing, IVT, Vaccination, PATH, Meningitis, Bill, Safety, Sepsis, Vaccine

Biotechnology company Inventprise Inc. today announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in young adults.

Key Points: 
  • Biotechnology company Inventprise Inc. today announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in young adults.
  • This Phase 2 study is an important step in the efforts to develop an affordable, expanded-coverage pneumococcal conjugate vaccine (PCV).
  • The Inventprise PCV includes 25 serotypes—expanding the potential to prevent several deadly and emerging serotypes not yet addressed by existing PCVs.
  • A Phase 2 study in older adults is also planned to take place in the second half of 2024.

RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation

Retrieved on: 
Friday, December 8, 2023
Research, Surgery, Medical Devices, Medical Supplies, FDA, Clinical Trials, Biotechnology, Health, Science, Subdural empyema, Safety, Food, Crystal skull, Risk, Aneurysm, CSF, Clinical trial, Multimedia, Skull, Infection, Osteoblast, MPH, Pain, Intracranial pressure, Cerebrospinal fluid, Meningitis, Architecture, Boston, MD, Brigham, Doctor of Philosophy

This approval was largely predicated on the successful pivotal preclinical and surgeon handling testing conducted by the company.

Key Points: 
  • This approval was largely predicated on the successful pivotal preclinical and surgeon handling testing conducted by the company.
  • As part of the surgical closure process, the cranial flap is secured back into place with plates and screws.
  • The kerf line, however, is typically not sealed, which compromises the ability of the flap to integrate with the surrounding bone.
  • “We are truly excited to move this project into the clinical phase of testing,” said Brian Hess, CEO and Founder of RevBio.

Katalin Karikó and Anne Schuchat Receive 2023 Fries Prize for Improving Health

Retrieved on: 
Sunday, November 12, 2023
DRS, Infant, Pneumonia, Nobel Prize, Cell, Epidemic Intelligence Service, GAVI, Immunization, CDC, Group B streptococcal infection, NCIRD, Doctor of Philosophy, USPHS, University of Szeged, COVID, Organization, Erich Fried Prize, Health, American Public Health Association, RADM, Parent, ARD International Music Competition, Letter, Public, Meningitis, RNA, Therapy, University of Pennsylvania, Anne Schuchat, Infection, APHA, University, RET, SARS, Research, Developmental Biology (journal), Death, Vaccine, Messenger, COVID-19, GBS, Nursing, Management, Pharmaceutical industry, Physiology, Ophthalmology, Medicine, MD

ATLANTA, Nov. 12, 2023 /PRNewswire/ -- Nobel Prize Winner Katalin Karikó, PhD, and former Centers for Disease Control and Prevention (CDC) Principal Deputy Director Anne Schuchat, MD (RADM, USPHS, RET), today received the 2023 Fries Prize for Improving Health.

Key Points: 
  • ATLANTA, Nov. 12, 2023 /PRNewswire/ -- Nobel Prize Winner Katalin Karikó, PhD, and former Centers for Disease Control and Prevention (CDC) Principal Deputy Director Anne Schuchat, MD (RADM, USPHS, RET), today received the 2023 Fries Prize for Improving Health.
  • The Fries Prize for Improving Health award was presented this morning at the American Public Health Association's (APHA) annual meeting, which is taking place in Atlanta.
  • The monetary award for the Fries Prize for Improving Health is $70,000, which will be divided between the recipients.
  • As of 2016, the CDC Foundation manages and administers the Fries Foundation's public health award programs, which include the Fries Prize for Improving Health and the Elizabeth Fries Health Education Award.

BioCina Expands Partnership with GPN Vaccines

Retrieved on: 
Monday, November 6, 2023
CGMP, Escherichia coli, Gamma, GPN, Vaccine, CDMO, Pneumonia, Meningitis, Death, A-DNA, Partnership, Streptococcus pneumoniae, Bacteria, Fungal infection, Streptococcus

ADELAIDE, South Australia, Nov. 6, 2023 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PN™ against Streptococcus pneumoniae.

Key Points: 
  • ADELAIDE, South Australia, Nov. 6, 2023 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PN™ against Streptococcus pneumoniae.
  • This bacterium is responsible for causing life-threatening infections such as pneumonia, bacteraemia and meningitis, each year causing up to 2 million deaths worldwide.
  • The BioCina facility in Adelaide, Australia has a rich history of developing and manufacturing recombinant proteins in microbial systems such as E. coli.
  • GPN Vaccines' Chairman & Chief Executive Officer, Professor Tim Hirst said, "We are delighted to be progressing with the next stage of cGMP manufacture of our innovative whole cell pneumococcal vaccine, Gamma-PN™, with BioCina as the CDMO of choice.

Solihull farmer takes on Atlantic row in son's memory

Retrieved on: 
Sunday, October 29, 2023
Always Look on the Bright Side of Life, Meningitis, Nature, Balsall Common, Get Ahead, Ageing, Awareness, Memory, BBC West Midlands, Whaling, Nursing, Facebook, Atlantic Ocean

Solihull farmer takes on Atlantic row in son's memory

Key Points: 
  • Solihull farmer takes on Atlantic row in son's memory
    - Published
    A farmer is preparing to row across the Atlantic ocean in memory of his son who died from meningitis.
  • Rod Adlington, from Balsall Common in Solihull, will be part of a four-man crew taking on the unaided 3,000 mile (4,828km) journey starting from Lanzarote.
  • His son Barney died from the illness 18 years ago, aged three.
  • He said he wants to raise awareness of the illness, and hopes to raise £250,000 for charity.